Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Up 244.7% in September

Akari Therapeutics PLC (NASDAQ:AKTX) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 84,800 shares, a growth of 244.7% from the August 31st total of 24,600 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 160,700 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 160,700 shares, the short-interest ratio is presently 0.5 days. Approximately 0.3% of the company’s shares are sold short.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Maxim Group assumed coverage on shares of Akari Therapeutics in a research report on Friday, July 18th. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $1.60 price target on shares of Akari Therapeutics in a research report on Tuesday, September 9th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $3.30.

Akari Therapeutics Stock Down 4.7%

NASDAQ:AKTX opened at $0.93 on Friday. The company has a 50-day moving average price of $0.91 and a 200-day moving average price of $1.13. Akari Therapeutics has a 12 month low of $0.57 and a 12 month high of $3.70.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.